только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 13 / 26
Страница 1 / 7

Список литературы

  1. Gallo R. C. [и др.]. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS // Science. 1984. № 4648 (224). C. 500–503.
  2. Popovic M. [и др.]. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS // Science. 1984. № 4648 (224). C. 497–500.
  3. Бартлетт Дж. [и др.]. Клинические аспекты ВИЧ-инфекции // ГРАНАТ-е изд., 2013. 696 c.
  4. Либман Говард, Харви Дж. Макадон ВИЧ-инфекция // ГЭОТАР-Мед-е изд., 2013. 560 c.
  5. Покровский В.В. ВИЧ-инфекция и СПИД Национальное руководство // ГЭОТАР-Мед-е изд., 2020.
    696 c.
  6. Беляков Н.А. [и др.]. Эпидемиология ВИЧ инфекции. Место мониторинга, научных и дозорных наблюдений, моделирования и прогнозирования обстановки. // ВИЧ-инфекция и иммуносупрессии, Том 11, № 2. 2019.
  7. Клиническая классификация ВИЧ-инфекции. Приложение к Инструкции по заполнению годовой формы государственного федерального статистического наблюдения № 61 "Сведения о контингентах больных ВИЧ-инфекцией", утвержденной Приказом Минздравсоцразвития России от 17.03.2006 г. № 166.
  8. Барлетт Д., Галлант Д., Фам П. Клинические аспекты ВИЧ-инфекции. 2009-2010 // Р.Валент-е изд., Unspecified, 2010. 490 c.
  9. Покровский В.В., ред. ВИЧ-инфекция и СПИД. Клинические рекомендации. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2010. 186 с.
  10. ВИЧ-инфекция и СПИД. Национальное руководство под ред. Покровский В.В., ГЭОТАР Мед-е изд., 2013. 608 c.
  11. Покровский В.В. [и др.]. Национальные рекомендации по диспансерному наблюдению и лечению ВИЧ-инфекцией. Клинический протокол. // Эпидемиология и инфекционные болезни. Актуальные вопросы №6. 2016. C. 120
  12. Постановление Главного государственного санитарного врача РФ от 28.01.2021 N 4 "Об утверждении санитарных правил и норм СанПиН 3.3686-21 "Санитарно-эпидемиологические требования по профилактике инфекционных болезней"
  13. Покровский В.В. [и др.]. ВИЧ-инфекция. Информационный бюллетень №43. 2018.
  14. Przybyla S. M. [и др.]. Meta-Analysis of Alcohol and Serodiscordant Condomless Sex Among People Living with HIV // Archives of Sexual Behavior. 2018. № 5 (47). C. 1351–1366.
  15. Smolak A. A meta-analysis and systematic review of HIV risk behavior among fishermen // AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV. 2014. Т. 26. № 3. C. 282–291.
  16. Wang Ze Dong [и др.]. Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis // The Lancet HIV. 2017. № 4 (4). C. е177-е188.
  17. Dianatinasab M. [и др.]. Prevalence of tuberculosis in HIV-positive prisoners: A systematic review and meta-analysis // AIDS Reviews. 2018. Т. 20. № 2. C. 114–124.
  18. Kouyoumjian S. P. [и др.]. Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence // AIDS. 2018. № 10 (32). C. 1343.
  19. Lan C. W. [и др.]. Prevalence of Alcohol Use, Sexual Risk Behavior, and HIV Among Russians in High-Risk Settings: a Systematic Review and Meta-Analysis // International Journal of Behavioral Medicine. 2017. № 2 (24). C. 180–190.
  20. Lei Jun Hao [и др.]. Circumcision status and risk of HIV acquisition during heterosexual intercourse for both males and females: A meta-analysis // PLoS ONE. 2015. № 5 (10).
  21. Svensson P. [и др.]. A meta-analysis and systematic literature review of factors associated with sexual risk-taking during international travel // Travel Medicine and Infectious Disease. 2018. Т. 24. C. 65–88.
  22. Platt L. [и др.]. Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-analysis // The Lancet Infectious Diseases. 2016. № 7 (16). C. 797–808.
  23. Low Andrea [и др.]. Incidence of Opportunistic Infections and the Impact of Antiretroviral Therapy among HIV-Infected Adults in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis // Clinical Infectious Diseases. 2016. № 12 (62).
  24. Sabbagh Parisa [и др.]. The global and regional prevalence, burden, and risk factors for methicillin-resistant Staphylococcus aureus colonization in HIV-infected people: A systematic review and meta-analysis // American Journal of Infection Control. 2019. Т. 47. № 3.
  25. Hamada Yohhei [и др.]. Sensitivity and specificity of WHO’s recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis // The Lancet HIV. 2018. № 9 (5). C. е515-е523.
  26. Henriquez-Camacho C. [и др.]. Opt-out screening strategy for HIV infection among patients attending emergency departments: systematic review and meta-analysis // HIV Medicine. 2017. № 6 (18).
  27. Gebrezgi M. T. [и др.]. Acceptance of Opt-Out HIV Screening in Outpatient Settings in the United States: A Systematic Review and Meta-Analysis // Public Health Reports. 2019. Т. 134. № 5.
  28. Smallwood M. [и др.]. Evaluation of a rapid point of care test for detecting acute and established HIV infection, and examining the role of study quality on diagnostic accuracy: A Bayesian meta-analysis // PLoS ONE. 2016. № 2 (11).
  29. Tan W. S. [и др.]. Sensitivity of HIV rapid tests compared with fourth-generation enzyme immunoassays or HIV RNA tests // AIDS. 2016. № 12 (30). C. 1951–1960.
  30. Sarinoğlu R. C. [и др.]. Evaluation of enzyme immunoassay (EIA), immunoblot and HIV RNA polymerase chain reaction test results in the diagnosis of human immunodeficiency virus (HIV) infection // Mikrobiyoloji Bulteni. 2019. № 4 (53). C. 401–407.
  31. Wu S. [и др.]. Prevalence of HIV Indeterminate Western Blot Tests and Follow-up of HIV Antibody Sero-Conversion in Southeastern China // Virologica Sinica. 2019. № 4 (34). C. 358–366.
  32. Babiker A. [и др.]. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis // AIDS Research and Human Retroviruses. 2000. № 12 (16). C. 1123–133.
  33. Fox M., McCarthy O., Over M. A Novel Approach to Accounting for Loss to Follow-Up when Estimating the Relationship between CD4 Count at ART Initiation and Mortality // PLoS ONE. 2013. № 7 (8).
  34. Baillargeon J., Grady J., Borucki M. J. Immunological predictors of HIV-related survival // International Journal of STD and AIDS. 1999. № 7 (10). C. 467–470.
  35. Kebede M., Zegeye D. T., Zeleke B. M. Predicting CD4 count changes among patients on antiretroviral treatment: Application of data mining techniques // Computer Methods and Programs in Biomedicine. 2017. (152). C. 149–157.
  36. Stephan C. [и др.]. Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: A meta-analysis of 12,370 patients in 21 clinical trials // HIV Medicine. 2013. № 5 (14).
    С. 284-292.
  37. EACS Guidelines Version 10, 2019 // https://www.eacsociety.org/media/eacs_gudelines_2019_rus.pdf.
  38. Murray J. S. [и др.]. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs // AIDS. 1999. № 7 (13). C. 797- 804
  39. Marschner I. C. [и др.]. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy // Journal of Infectious Diseases. 1998. № 1 (177). C. 40-47.
  40. Laprise C. [и др.]. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: Results from 12 years of observation // Clinical Infectious Diseases. 2013. № 10 (57). C. 1489–1496.
  41. Wankah P. N., Tagny C. T., Mbanya D. N. S. Profile of blood cell abnormalities among antiretroviral therapy naïve HIV patients attending the Yaounde University Teaching Hospital, Cameroon // BMC Hematology. 2014. № 1 (14). С. 15.
  42. Fellay J. [и др.]. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study // Lancet. 2001. № 9290 (358). С. 1322–1327.
  43. Mapanga W. [и др.]. Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer screening: A systematic review // Systematic Reviews. 2018. Т. 7. № 1. С. 198.
  44. Liu G. [и др.]. HIV-positive women have higher risk of human papillomavirus infection, precancerous lesions, and cervical cancer // AIDS. 2018. № 6 (32). С. 795-808.
  45. Ucciferri C. [и др.]. Prevalence of anal, oral, penile and urethral human papillomavirus in HIV infected and HIV uninfected men who have sex with men // Journal of Medical Virology. 2018. № 2 (90). С. 358-366.
  46. Clifford G. M., Tully S., Franceschi S. Carcinogenicity of human papillomavirus (HPV) types in HIV-positive women: A meta-analysis from HPV infection to cervical cancer // Clinical Infectious Diseases. 2017. № 9 (64). С. 1228-1235.
  47. King E. M. [и др.]. Oral human papillomavirus infection in men who have sex with men: A systematic review and meta-analysis // PLoS ONE. 2016. № 7 (11).
  48. Islam F. M. [и др.]. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. // BMC public health. 2012. Т. 12. С. 234.
  49. Ekrikpo U. E. [и др.]. Chronic kidney disease in the global adult HIV-infected population: A systematic review and meta-analysis // PLoS ONE. 2018. Т. 13. № 4.
  50. Barraclough K. [и др.]. A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population // Nephron - Clinical Practice. 2009. № 1 (111). С. c39-c48.
  51. Ford N. [и др.]. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis // Clinical Infectious Diseases. 2018. (66). С. S152-S159.
  52. Diedrich C. R., O’Hern J., Wilkinson R. J. HIV-1 and the Mycobacterium tuberculosis granuloma: A systematic review and meta-analysis // Tuberculosis. 2016. Т. 98. C. 62–76.
  53. Khademi F. [и др.]. Bacterial Co-infections in HIV/AIDS-positive Subjects: A Systematic Review and Meta-analysis // Folia medica. 2018. № 3 (60). С. 339-350.
  54. Chapter 6: Service Delivery (Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection) // World Health Organisation (WHO). 2015.
  55. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendation for the public health approach. WHO 2nd edition. 2016.
  56. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC). 2016.
  57. Jürgen K. Rockstroh, Christian Hoffmann HIV 2015/2016 / Fo-е изд., Hamburg, 2015. С. 776с.
  58. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations,2016 update. // World Health Organisation (WHO).
  59. Лисицина З.Н. [и др.]. Иммунные тесты и диагностика острой стадии ВИЧ-инфекции. ВИЧ-инфекция и иммуносупрессии // ВИЧ-инфекция и иммуносупрессии. 2017. № 2 (9). C. 36–41.
  60. Рекомендации по диагностике и лечению взрослых больных гепатитом С // МАСОИ-е изд., Москва, 2017. С. 69.
  61. Bystryak S., Ossina N. A rapid ultrasound particle agglutination method for HIV antibody detection: Comparison with conventional rapid HIV tests // Journal of Virological Methods. 2017. (249). C. 38–47.
  62. Scott R. K., Crochet S., Huang C. C. Universal Rapid Human Immunodeficiency Virus Screening at Delivery: A Cost-Effectiveness Analysis // Infectious Diseases in Obstetrics and Gynecology. 2018. (2018).
  63. Владимиров К. Б., Марфина Г. Ю., Иванов А. К Роль флюорографического обследования в выявлении туберкулёза у больных с ВИЧ-инфекцией в пенитенциарных учреждениях // ВИЧ-инфекция и иммуносупрессии. 2015. Т. 7. № 2. C. 69–76.
  64. Nduka C. U. [и др.]. Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: A systematic review with meta-analysis // Journal of Human Hypertension. 2016. Т. 30. № 6. C. 355–362.
  65. Patel N. [и др.]. Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation // HIV Medicine. 2013. № 8 (14). C. 463–471.
  66. Xu Y., Chen X., Wang K. Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis // Journal of the American Society of Hypertension. 2017. Т. 11. № 8. C. 530–540.
  67. Hoving D. J. Van [и др.]. Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals // Cochrane Database of Systematic Reviews. 2019. Т. 2019. № 9.
  68. N’Gbesso R. D. [и др.]. Renal insufficiency: comparison of ultrasound and laboratory profiles in HIV-negative and HIV-positive patients // Cahiers Sante. 2005. № 3 (15). C. 183–187.
  69. Ulu U. O., Agbaji O., Agwu K. K. Sonographic characterization of renal pathologies in HIV/AIDS in Plateau State, Nigeria. // Nigerian journal of medicine: journal of the National Association of Resident Doctors of Nigeria. 2012. № 2 (21). C. 160.
  70. Granata A. [и др.]. [Ultrasound assessment in renal infections]. // Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia. 2012. (29 Suppl 5). C. 47–57.
  71. Krikke M. [и др.]. Cardiovascular risk prediction in HIV-infected patients: Comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti- // HIV Medicine. 2016. № 4 (17).
  72. Gupta M. [и др.]. Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection // American Journal of Cardiology. 2013. № 5 (111). C. 760–764.
  73. Ssentongo P. Prevalence and incidence of new-onset seizures and epilepsy in patients with human immunodeficiency virus (HIV): Systematic review and meta-analysis // Epilepsy and Behavior. 2019. Т. 93. C. 49–55.
  74. O’Connor E. E., Zeffiro T. A., Zeffiro T. A. Brain structural changes following HIV infection: Meta-analysis // American Journal of Neuroradiology. 2018. № 1 (39). C. 54–62.
  75. Sin N. L., DiMatteo M. R. Depression treatment enhances adherence to antiretroviral therapy: A meta-analysis // Annals of Behavioral Medicine. 2014. № 3 (47). C. 259–269.
  76. Luo Z. [и др.]. Lifetime prevalence of suicidal ideation among men who have sex with men: A meta-analysis // BMC Psychiatry. 2017. № 1 (17). C. 1–9.
  77. Gandhi M. [и др.]. Sex Differences in Pharmacokinetics and Pharmacodynamics // Annual Review of Pharmacology and Toxicology. 2004. Т. 44. C. 499–523.
  78. Ofotokun I., Chuck S. K., Hitti J. E. Antiretroviral pharmacokinetic profile: A review of sex differences // Gender Medicine. 2007. № 2 (4). C. 106–119.
  79. Ford N. [и др.]. Safety of efavirenz in the first trimester of pregnancy: An updated systematic review and meta-analysis // AIDS. 2014. Т. 28. № SUPPL. 2. C. 123–131.
  80. Zhang J. [и др.]. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women // Antiviral Therapy. 2011. № 2 (16). C. 157–164.
  81. Vogler M. A. [и др.]. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: Pharmacokinetic results of ACTG trial A5188 // Journal of Acquired Immune Deficiency Syndromes. 2010. № 4 (55). C. 473–482. 
  82. Stuart G. S. [и др.]. Combined oral contraceptives and antiretroviral PK/PD in Malawian women: Pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi // Journal of Acquired Immune Deficiency Syndromes. 2011. Т. 58. № 2. C. 40–43.
  83. World Health Organization. Hormonal contraceptive methods for women at high risk of HIV and living with HIV 2014. Guidance statement. Geneva, 2014.
  84. Low Andrea [и др.]. Incidence of Opportunistic Infections and the Impact of Antiretroviral Therapy among HIV-Infected Adults in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis // Clinical Infectious Diseases. 2016. № 12 (62).
  85. Ford N. [и др.]. Causes of hospital admission among people living with HIV worldwide: A systematic review and meta-analysis // The Lancet HIV. 2015. № 10 (2). C. e438–e444.
  86. Farahani M. [и др.]. Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis // International Journal of STD and AIDS. 2017. Т. 28. № 7. C. 636–650.
  87. Gutierrez J., Albuquerque A. L. A., Falzon L. HIV infection as vascular risk: A systematic review of the literature and meta-analysis // PLoS ONE. 2017. Т. 12. № 5.
  88. Poorolajal J. [и др.]. Survival rate of AIDS disease and mortality in HIV-infected patients: a meta-analysis // Public Health. 2016. Т. 139. C. 3–12.
  89. Kanters S. [и др.]. Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis // The Lancet HIV. 2017. № 1 (4). C. 31–40.
  90. Costa J. D. M. [и др.]. Adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean: Systematic review and meta-analysis: Systematic // Journal of the International AIDS Society. 2018. Т. 21. № 1.
  91. Bock P. [и др.]. Baseline CD4 count and adherence to antiretroviral therapy: A systematic review and meta-analysis // Journal of Acquired Immune Deficiency Syndromes. 2016. Т. 73. № 5. C. 514–521.
  92. Song A. [и др.]. From CD4-based initiation to treating all HIV-infected adults immediately: An evidence-based meta-analysis // Frontiers in Immunology. 2018. № FEB (9). C. 212.
  93. Siegfried N., Uthman O. A., Rutherford G. W. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults // Cochrane Database of Systematic Reviews. 2010. №3.
  94. Sturt A. S., Dokubo E. K., Sint T. T. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women // Cochrane Database of Systematic Reviews. 2010. №. 3.
  95. Kourtis A. P. [и др.]. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: A meta-analysis // AIDS. 2007. № 5 (21). C. 607–615.
  96. Uthman O. A. [и др.]. Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis // The Lancet HIV. 2017. № 1 (4). C. е21–е30.
  97. Gupta A. [и др.]. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): A systematic review and meta-analysis // PLoS ONE. 2011. Т. 6. № 12.
  98. Grinsztejn B. [и др.]. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: Results from the phase 3 HPTN 052 randomised controlled trial // The Lancet Infectious Diseases. 2014. № 4 (14).
  99. McCarthy J., Maine D. A Framework for Analyzing the Determinants of Maternal Mortality // Studies in Family Planning. 1992. № 1 (23).
  100. Gout C. [и др.]. Assisted Reproductive Technologies in HIV patients: A comprehensive review of indications, techniques and results // Gynecologie Obstetrique et Fertilite. 2011. № 12 (39). C. 704–708.
  101.  Anglemyer A. [и др.]. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples 2011.
  102. Ford N. [и др.]. Benefits and risks of rapid initiation of antiretroviral therapy // AIDS. 2018. № 1 (32). C. 17.
  103. Eshun-Wilson I. [и др.]. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis // Cochrane Database of Systematic Reviews. 2018. Т. 2018. № 7.
  104. Kourtis A. P. [и др.]. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: A meta-analysis // AIDS. 2007. № 5 (21). C. 607–615.
  105. Pozniak A., Hospital W., Alison Rodger L. British HIV Association guidelines on the use of vaccines in HIV-positive adults. 2015.
  106. Günthard H. F. [и др.]. Antiretroviral drugs for treatment and prevention of HIV infection in Adults: 2016 recommendations of the international antiviral society-USA Panel // JAMA - Journal of the American Medical Association. 2016. № 2 (316). C. 191–210.
  107. Recommendations of the International Antiviral Society-USA Panel // JAMA - Journal of the American Medical Association. 2016. № 2 (316). C. 191–210.
  108. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ // Эпидемиология и инфекционные болезни. Актуальные вопросы. Прил. 2019. (4). C. 1–87.
  109. Clay P. G. [и др.]. Meta-Analysis of studies comparing single and multi-Tablet fixed dose combination HIV treatment regimens // Medicine (United States). 2015. Т. 94. № 42.
  110. Sweet D. E. [и др.]. Cost-effectiveness of single-versus generic multiple-tablet regimens for treatment of HIV-1 infection in the United States // PLoS ONE. 2016. № 1 (11).
  111. Systematic reviews and meta-analyses informing the guidelines on the public health response to pretreatment HIV drug resistance. Web Annex 2. Geneva: World Health Organization; 2017 (http://www.who.int/hiv/topics/drugresistance/en).  
  112. Uthman O. A. [и др.]. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: A systematic review and meta-analysis // Annals of Internal Medicine. 2015. Т. 163. № 1. C. 32–39.
  113. Aves T. [и др.]. Antiretroviral resistance testing in HIV-positive people // Cochrane Database of Systematic Reviews. 2018. Т. 2018. № 11.
  114. Goh S. S. L. [и др.]. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors // Osteoporosis International. 2018. № 3 (29). C. 595–613.
  115. Msoka T. F. [и др.]. The effect of HIV infection, antiretroviral therapy on carotid intima-media thickness: A systematic review and meta-analysis // Life Sciences. 2019. Т. 235.
  116. Al-Dakkak I. [и др.]. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: A systematic review and meta-analysis // AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV. 2013. Т. 25. № 4. C. 400–414.
  117. Bedimo R., Rosenblatt L., Myers J. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection // HIV Clinical Trials. 2016. Т. 17. № 6. C. 246.
  118. Stainsby C. M. [и др.]. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure // Pharmacotherapy. 2019. № 1 (39). C. 40–54.
  119. Tangamornsuksan W. [и др.]. Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: A systematic review and meta-analysis // Journal of Pharmacy and Pharmaceutical Sciences. 2015. № 1 (18). C. 68–76.
  120. Mirgh S. [и др.]. Refractory anemia in human immunodeficiency virus: Expect the unexpected // Journal of Family Medicine and Primary Care. 2016. № 3 (5).
  121. Fischl M. A. [и др.]. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial // New England Journal of Medicine. 1987. № 4 (317).
  122. Liu PT [и др.]. Study on the relationship between HIV drug resistance and CD4(+) T cell counts among antiretroviral therapy patients with low viral load // Zhonghua Yu Fang Yi Xue Za Zhi [Chinese journal of preventive medicine]. 2018. (3).
  123. Trinité B., Zhang H., Levy D. N. NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal // Retrovirology. 2019. № 1 (16).
  124. Cai J., Osikowicz M., Sebastiani G. Clinical significance of elevated liver transaminases in HIV-infected patients // AIDS. 2019. Т. 33. № 8. С. 1267-1282.
  125. Lafaurie M. [и др.]. Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: A case-control study // PLoS ONE. 2014. № 11 (9)
  126. Taramasso L. [и др.]. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA) // BMC Infectious Diseases. 2018. № 1 (18)
  127. Ramjan R. [и др.]. Systematic review and meta-analysis: Patient and programme impact of fixed-dose combination antiretroviral therapy // Tropical Medicine and International Health. 2014. № 5 (19). C. 501–513.
  128. Snedecor S. J. [и др.]. Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: A systematic review and meta-analysis // AIDS Research and Human Retroviruses. 2014. № 8 (30). C. 753–768.
  129. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis // The Lancet Infectious Diseases. 2018. № 3 (18).
  130. Panel on Clinical Practices for Treatment of HIV Infection et al. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents // African journal of medical practice. 1998. C. 79.
  131. Sax P. E. [и др.]. Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy // New England Journal of Medicine. 2009. № 23 (361). C. 2230–2240.
  132. Post F. A. [и др.]. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study // Journal of Acquired Immune Deficiency Syndromes. 2010. № 1 (55). C. 49–57.
  133. Stellbrink H. J. [и др.]. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomized, double-blind, multicentre, phase 3, non-infer // The Lancet HIV. 2019. № 6 (6). C. 364–372.
  134. Mendes J. C. [и др.]. Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy // European Journal of Clinical Pharmacology. 2018. № 8 (74). C. 1077–1088.
  135. Jiang J. [и др.]. Dolutegravir (DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: A meta-analysis of randomized controlled trials // AIDS Research and Therapy. 2016. № 1 (13).
  136. Кравченко А.В. [и др.]. Эффективность и безопасность нового российского ненуклеозидного ингибитора обратной транскриптазы элсульфавирина в первой линии лечения ВИЧ-инфекции в комбинации с двумя нуклеозидными/нуклеотидными ингибиторами обратной транскриптазы – исследование 96 нед. // Журнал инфектологии. 2018. № 2 (10). C. 76–82.
  137. Кравченко А.В. [и др.]. Оценка безопасности, переносимости, фармакокинетики и лекарственных взаимодействий применения препарата элсульфавирин у здоровых добровольцев и пациентов с нарушением функции печени // Инфекционные болезни. 2020. № 2 (18). C. 40–46.
  138. Покровский В.В. [и др.]. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ // Эпидемиология и инфекционные болезни. Актуальные вопросы. 2019. (№4). C. 87.
  139. Trottier B. [и др.]. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study // Antiviral Therapy. 2017. № 4 (22). C. 295–305.
  140. Dickinson L. [и др.]. Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study // Clinical Pharmacokinetics. 2016. № 7 (55). C. 861–873.
  141. Dubrocq G., Rakhmanina N. The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection // Expert Opinion on Drug Metabolism and Toxicology. 2018. № 8 (14). C. 773–779.
  142. Sax P. E. [и др.]. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomized, double-blind, phase 3, non-inferiority trials // The Lancet. 2015. № 9987 (385). C. 2606–2615.
  143. Wohl D. [и др.]. A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results // JAIDS Journal of Acquired Immune Deficiency Syndromes. 2016. № 1 (72). C. 58–64.
  144. Post F. Adverse events: ART and the kidney: alterations in renal function and renal toxicity // Journal of the International AIDS Society. 2014. (17).
  145. Cooper R. D. [и др.]. Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in hiv-infected patients // Clinical Infectious Diseases. 2010. Т. 51. № 5. C. 496–505.
  146. Arg M. [и др.]. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Developed by the DHHS Panel on Antiretroviral Guidelines for Adults // Journal of Ethnopharmacology. 2016. № January (5).
  147. Kouanfack C. [и др.]. Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1 // New England Journal of Medicine. 2019. № 9 (381). C. 816–826.
  148. Бобкова М.Р. Лекарственная устойчивость ВИЧ. М.: Человек, 2014. С. 288
  149. Rutherford G. W. [и др.]. Predicting treatment failure in adults and children on antiretroviral therapy: A systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure // AIDS. 2014. № SUPPL. 2 (28).
  150. M. Dabrowska M., Mikula T., Wiercinska-Drapalo A. The Anemia Prevalence and the Association Between Complete Blood Count Analysis and Renal Function Parameters in HIV-1-Infected Patients // Current HIV Research. 2012. № 3 (10). C. 247–251.
  151. Gallant J. [и др.]. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomized controlled non-inferiority trial // The Lancet. 2017. № 10107 (390). C. 2063–2072.
  152. Brenner B. G. [и др.]. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors // Journal of Antimicrobial Chemotherapy. 2016. № 7 (71).
  153. Clay P. G. [и др.]. Meta-Analysis of studies comparing single and multi-Tablet fixed dose combination HIV treatment regimens // Medicine (United States). 2015. Т. 94. № 42.
  154. Pialoux G. [и др.]. Cost-effectiveness of dolutegravir in HIV-1 treatment-experienced (TE) patients in France // PLoS ONE. 2015. № 12 (10).
  155. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendation for the public health approach. WHO 2nd edition. 2016.
  156. Sweet D. E. [и др.]. Cost-effectiveness of single-versus generic multiple-tablet regimens for treatment of HIV-1 infection in the United States // PLoS ONE. 2016. № 1 (11).
  157. Galen K. A. Van, Nellen J. F., Nieuwkerk P. T. The Effect on Treatment Adherence of Administering Drugs as Fixed-Dose Combinations versus as Separate Pills: Systematic Review and Meta-Analysis // AIDS Research and Treatment. 2014. Т. 2014.
  158. Clay P. G. [и др.]. A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV // AIDS Research and Therapy. 2018. № 1 (15). C. 17.
  159. D’Ascenzo F. [и др.]. A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era // Journal of Cardiovascular Medicine. 2015. № 12 (16). C. 839–843.
  160. Unsal A. B. [и др.]. Effect of antiretroviral therapy on bone and renal health in young adults infected with HIV in early life // Journal of Clinical Endocrinology and Metabolism. 2017. № 8 (102). C. 2896–2904.
  161. Boender T. S. [и др.]. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: A systematic review and meta-analysis // Clinical Infectious Diseases. 2015. Т. 61. №9.
  162. Mark Marzinke Therapeutic Drug Monitoring of Antiretrovirals. . Clinical Challenges in Therapeutic Drug Monitoring / Mark Marzinke, 2016. 135–163 c.
  163. Achhra A. C. [и др.]. Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis // The Lancet HIV. 2016. № 8 (3). C. 351–360.
  164. Langebeek N. [и др.]. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: A meta-analysis // BMC Medicine. 2014. № 1 (12). C. 1–14.
  165. Corado K. C., Caplan M. R., Daar E. S. Two-drug regimens for treatment of naïve HIV-I infection and as maintenance therapy // Drug Design, Development and Therapy. 2018. Т. 12. C. 3731.
  166. Wyk J. Van [и др.]. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living with Human Immunodeficiency Virus Type 1: Phase // Clinical Infectious Diseases. 2020. № 8 (71).
  167. Gill P. S. [и др.]. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma // Journal of Clinical Oncology. 1996. № 8 (14). C. 2353–2364.
  168. Skiest D. J. [и др.]. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection // Clinical Infectious Diseases. 2007. № 4 (44). C. 607–614.
  169.  Corti M., Palmero D. J. Mycobacterium avium complex infection in HIV/AIDS patients // Expert Review of Anti-Infective Therapy. 2008. Т. 6. № 3. C. 351–363.
  170. Frankel E. N. Chemistry of free radical and singlet oxidation of lipids // Progress in Lipid Research. 1984. Т. 23. № 4.
  171. Karakousis P. C., Moore R. D., Chaisson R. E. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy // Lancet Infectious Diseases. 2004. Т. 4. № 9. C. 557–565.
  172. Chaisson R. E. [и др.]. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection // AIDS. 1997. № 3 (11). C. 311–317.
  173. Benson C. A. [и др.]. A Prospective, Randomized Trial Examining the Efficacy and Safety of Clarithromycin in Combination with Ethambutol, Rifabutin, or Both for the Treatment of Disseminated Mycobacterium avium Complex Disease in Persons with Acquired Immunodeficiency Syndrome // Clinical Infectious Diseases. 2003. № 9 (37). C. 1234–1243.
  174. Moyle G. J., Gill J., Nelson M. Once weekly azithromycin as prophylaxis against recurrence of non-tuberculous mycobacterial infections in HIV-1-positive individuals [4] // AIDS. 1998. Т. 12. № 12. C. 1555–1557.
  175. J. Vidanapathirana [и др.]. Mass media interventions for promoting HIV testing // Cochrane database of systematic reviews (Online). 2005. № 3.
  176. Meader N. [и др.]. Psychosocial interventions for the reduction of injection and sexual risk behaviour for preventing HIV in drug users // Cochrane Database of Systematic Reviews. 2008. № 2.
  177. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring: March 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO
  178. Rotheram-Borus M. J., Cantwell S., Newman P. A. HIV prevention programs with heterosexuals // AIDS, Supplement. 2000. Т. 14. № 2.
  179. Merson M. H., Dayton J. M., O’Reilly K. Effectiveness of HIV prevention interventions in developing countries // AIDS, Supplement. 2000. Т. 14. № 2
  180. Neumann M. S. [и др.]. Review and meta-analysis of HIV prevention intervention research for heterosexual adult populations in the United States // Journal of Acquired Immune Deficiency Syndromes. 2002. Т. 30. № SUPPL. 1

181. Faust L., Yaya S. The effect of HIV educational interventions on HIV-related knowledge, condom use, and HIV incidence in sub-Saharan Africa: A systematic review and meta-analysis // BMC Public Health. 2018. Т. 18. №1.

182. Evangeli M., Pady K., Wroe A. L. Which Psychological Factors are Related to HIV Testing? A Quantitative Systematic Review of Global Studies // AIDS and Behavior. 2016. № 4 (20). C. 880–918.

183. Covey J., Rosenthal-Stott H. E. S., Howell S. J. A synthesis of meta-analytic evidence of behavioral interventions to reduce HIV/STIs // Journal of Behavioral Medicine. 2016. Т. 39. № 3. C. 371–385.

184.Ruiz-Perez I. [и др.]. The effectiveness of HIV prevention interventions in socioeconomically disadvantaged ethnic minority women: A systematic review and meta-analysis // American Journal of Public Health. 2017. Т. 107. № 12. C. 13–21.

185.Gause N. K. [и др.]. Meta-analyses of HIV prevention interventions targeting improved partner communication: effects on partner communication and condom use frequency outcomes // Journal of Behavioral Medicine. 2018. № 4 (41). C. 423–440

186.Yi S. [и др.]. Awareness and willingness to use HIV pre-exposure prophylaxis among men who have sex with men in low- and middle-income countries: A systematic review and meta-analysis: A // Journal of the International AIDS Society. 2017. Т. 20. № 1.

187.Lacroix J. M. [и др.]. Effectiveness of mass media interventions for HIV prevention, 1986-2013: A meta-analysis // Journal of Acquired Immune Deficiency Syndromes. 2014. № SUPPL.3 (66). C. 329–340.

188.Mize S. J. S. [и др.]. Meta-analysis of the effectiveness of HIV prevention interventions for women // AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV. 2002. № 2 (14). C. 163–180.

189.Marks G. [и др.]. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: Implications for HIV prevention programs // Journal of Acquired Immune Deficiency Syndromes. 2005. № 4 (39).

190.Scholten M. [и др.]. To prescribe, or not to prescribe: decision making in HIV-1 post-exposure prophylaxis // HIV Medicine. 2018. № 9 (19). C. 645–653.

191.Ford N. [и др.]. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: A systematic review // Clinical Infectious Diseases. 2015. Т. 60. C. 170–175.

192.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendation for the public health approach. WHO 2nd edition. 2016.

193.Ford N. [и др.]. Adherence to HIV postexposure prophylaxis: A systematic review and meta-analysis // AIDS. 2014. Т. 28. № 18. C. 2721–2727.

194.Ippolito G. The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection // Archives of Internal Medicine. 1993. № 12 (153).

195.Bell D. M. Occupational risk of human immunodeficiency virus infection in healthcare workers: An overview 1997.C. 9–15.

196.Kuhar D. T. [и др.]. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis // Infection Control & Hospital Epidemiology. 2013. № 9 (34). C. 875–892.

197.Tarantola A., Abiteboul D., Rachline A. Infection risks following accidental exposure to blood or body fluids in health care workers: A review of pathogens transmitted in published cases // American Journal of Infection Control. 2006. Т. 34. № 6.

198.Bock P. [и др.]. Baseline CD4 count and adherence to antiretroviral therapy: A systematic review and meta-analysis // Journal of Acquired Immune Deficiency Syndromes. 2016. Т. 73. № 5. C. 514–521.

199.Siegfried N., Uthman O. A., Rutherford G. W. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults // Cochrane Database of Systematic Reviews. 2010.

200.Horvath T. [и др.]. Interventions for preventing late postnatal mother-to-child transmission of HIV // Cochrane Database of Systematic Reviews. 2009. № 1.

201.Drake A. L. [и др.]. Incident HIV during Pregnancy and Postpartum and Risk of Mother-to-Child HIV Transmission: A Systematic Review and Meta-Analysis // PLoS Medicine. 2014. № 2 (11).

202.Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized non-inferiority trial // The Lancet. 2010. № 9709 (375). C. 123–131.

203.Ammassari A. [и др.]. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection // Journal of Acquired Immune Deficiency Syndromes. 2001. № 5 (28). C. 445–449.

204.Chen R. Y. [и др.]. Complete blood cell count as a surrogate CD4 cell marker for HIV monitoring in resource-limited settings // Journal of Acquired Immune Deficiency Syndromes. 2007. № 5 (44). C. 525–530.

205.Vervoort S. C. J. M. [и др.]. The role of HIV nursing consultants in the care of HIV-infected patients in Dutch hospital outpatient clinics // Patient Education and Counseling. 2010. № 2 (80). C. 180–184.

206.Fellay J. [и др.]. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study // Lancet. 2001. № 9290 (358). C. 1322–1327

207.Simoni J. M. [и др.]. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management // AIDS and Behavior. 2006. Т. 10. № 3. C. 227–245.

208.Gravemann S. [и др.]. Low-grade proteinuria is highly prevalent in HIV-positive patients on antiretroviral treatment // AIDS. 2014. № 12 (28). C. 1783–1789.

Для продолжения работы требуется вход / регистрация